Sergio Iadevaia, Ph.D.
Affiliations: | 2008 | Rice University, Houston, TX |
Area:
Chemical EngineeringGoogle:
"Sergio Iadevaia"Parents
Sign in to add mentor| Kyriacos Zygourakis | grad student | 2008 | Rice University (E-Tree) | |
| (Design of artificial genetic networks to regulate the biosynthesis of polyhydroxyalkanoate copolymers with desirable structures.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Camblin AJ, Tan G, Curley MD, et al. (2019) Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Scientific Reports. 9: 16832 |
| Camblin AJ, Pace EA, Adams S, et al. (2018) Dual inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and nab-paclitaxel in preclinical models of pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Curley MD, Tan G, Yannatos I, et al. (2016) Abstract 1209: Istiratumab (MM-141), a bispecific antibody targeting IGF-1R and ErbB3, inhibits pro-survival signaling in vitro and potentiates the activity of standard of care chemotherapy in vivo in ovarian cancer models Cancer Research. 76: 1209-1209 |
| Pace E, Adams S, Camblin A, et al. (2015) Effect of MM-141 on gemcitabine and nab-paclitaxel potentiation in preclinical models of pancreatic cancer through induction of IGF-1R and ErbB3 degradation. Journal of Clinical Oncology. 33: 289-289 |
| Masson K, Grantcharova V, Burenkova O, et al. (2015) Abstract LB-243: The ErbB3-targeting antibody MM-121 (seribantumab) reverses heregulin-driven resistance to multiple chemotherapies on tumor cell growth Cancer Research. 75 |
| Lugovskoy AA, Curley M, Baum J, et al. (2015) Abstract CT237: Preclinical characterization and first-in-human study of MM-141, a dual antibody inhibitor of IGF-1R and ErbB3 Cancer Research. 75 |
| Adams S, Curley MD, Camblin AJ, et al. (2015) Abstract A89: Istiratumab (MM-141), a bispecific antibody co-targeting IGF-1R and ErbB3, potentiates the activity of immune checkpoint inhibitors Molecular Cancer Therapeutics. 14 |
| Iadevaia S, Nakhleh LK, Azencott R, et al. (2014) Mapping network motif tunability and robustness in the design of synthetic signaling circuits. Plos One. 9: e91743 |
| Fitzgerald JB, Johnson BW, Baum J, et al. (2014) MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Molecular Cancer Therapeutics. 13: 410-25 |
| Adams S, Baum J, Sparta B, et al. (2013) Abstract C169: MM-141, a bispecific antibody inhibitor of PI3K/AKT/mTOR, attenuates tumor growth and potentiates everolimus in mouse models of anti-hormonal therapy-resistant ER/PR+ breast cancer. Molecular Cancer Therapeutics. 12 |